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1. Introduction
Tuberculosis (TB) is an infection dis-
ease affecting about one third of the 
world’s population.[1] The pulmonary 
route is the principal route of infec-
tion that initiates when Mycobacterium 
tuberculosis (Mtb) bacilli are inhaled and 
phagocytized by alveolar macrophages. 
However, some bacilli are able to sur-
vive within macrophage phagosomes 
leading to granuloma tissue formation 
that hampers an efficient treatment.[2] The 
prolonged treatment regimens and the 
toxic side effects resultant from oral/inject-
able administration of multiple drugs and 
dosages lead to reduced patient compli-
ance that further increases the chances 
of development of multidrug-resistant 
strains.[3] Thus, there is an urgent demand 
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for new anti-TB drugs and improved carriers systems for their 
effective delivery into the lower airways and alveoli.
The administration of inhalable drugs offers advantages in 
comparison to conventional routes which include targeting 
drugs directly to the infected area increasing local drug concen-
tration and reducing side effects.[4] Inhalable carrier systems in 
opposition to pure drug formulations allow protection of drugs 
avoiding their early degradation and fast clearance. Moreover, 
drug carriers allow to control and sustain the release of drugs 
over long periods of time and improve drug uptake by alveolar 
macrophages.[5]
Dry powder formulations are currently being considered 
among the most promising delivery systems for pulmonary 
administration.[6] As a result of their dehydrated form, dry 
powder formulations demonstrate higher physicochemical 
stability even under unrefrigerated conditions, thus extending 
their long-term storage outside of the cold chain. Further-
more, and unlike other inhaler devices, dry powder inhalers 
are propellant free, portable, easy to operate and cost-effective. 
However, inhalable formulations must encompass particular 
physicochemical properties which justify a considerable 
particulate engineering effort. For an effective deposition 
in the pulmonary alveoli, the optimal aerodynamic diameter of 
the particles should range from 1 to 5 µm.[7] Moreover, when 
the physical diameter meets the phagocytic size range capacity 
of alveolar macrophages (1–6 µm), it is possible to guide the 
particles into infected macrophages, which is advantageous for 
TB therapies as this approach leads to an intracellular influx of 
drug with potential to neutralize Mtb bacilli.[8]
This work aims to design and develop inhalable multifunc-
tional microparticulate systems with magnetic responsive-
ness for an effective pulmonary delivery of an anti-TB drug 
candidate (P3), into alveoli and alveolar macrophages, as a 
new approach toward improved TB treatment. Purine deriva-
tives have been described as antimycobacterial agents and P3 
is a 9-arylpurine derivative shown to have relevant anti-TB 
activity and low toxicity in both bone-marrow derived mac-
rophages (BMDMs) and VERO mammalian cells.[9] The micro-
particles (MPs) were fabricated with gelatin and bovine serum 
albumin (BSA) using a “cast” strategy by replicating the struc-
ture of spherical and porous calcium carbonate (CaCO3) tem-
plates.[10] Gelatin is a biocompatible, biodegradable, nontoxic 
and cost-effective natural polymer that has already been pro-
posed as carrier for pulmonary delivery of anti-TB drugs.[11] 
Due to P3 hydrophobic character, the MPs were filled with 
BSA, a natural delivery vehicle for hydrophobic drugs.[12] To 
shape and stabilize the MPs before loading P3, MPs were 
crosslinked with genipin, a natural amine reactive cross-linker, 
reported to have lower cytotoxicity than traditional chemicals as 
glutaraldehyde.[10c]
To provide magnetic responsiveness, superparamagnetic 
iron oxide nanoparticles (SPIONs) were incorporated into 
the MPs. The manipulation of magnetic elements such as 
SPIONs within inhalable systems were shown to enable guid-
ance and concentration of drugs to a desired lung region, 
improving treatment’s efficiency and minimizing side 
effects.[13] Furthermore, SPIONs can be remotely activated 
under the influence of an external magnetic field allowing 
controlled drug delivery.[14]
Overall, the proposed system consisting of a new anti-TB 
drug in a finely tailored and magnetically responsive inhalable 
dry powder is expected to delivery P3 into the lower airways 
and to be phagocytized by macrophages. Moreover, the release 
profile of P3 can be triggered and modulated by the applica-
tion of an external alternate magnetic field (AMF). Since the 
presence of SPIONs within MPs can be activated by magneto-
therapy devices triggering drug release with the desired dosage 
and frequency, this approach is envisioned to contribute for 
improved efficiency of future TB treatments using pharmaco-
logical drugs.
2. Results and Discussion
2.1. Characterization of Unloaded MPs
The drug carrier shape and size are extremely important param-
eters in pulmonary drug delivery to ensure well-defined aero-
dynamic properties and also for the phagocytic process of 
MPs. Thus, unloaded MPs were freeze dried and their shape 
and size evaluated by scanning electron microscopy (SEM) 
(Figure 1A1,A2). SEM analysis showed that MPs display the 
spherical shape from the initial CaCO3 templates. Unlike 
previous reports on similar gelatin casted microgels produced 
without using BSA as filler,[10c] the developed MPs did not 
collapse after drying, keeping the desired spherical structure of 
the CaCO3 template. The histogram of the dia meter frequency 
distribution of the dried MPs is shown in Figure 1B as along 
with their normal distribution function. Dry MPs present a 
diameter of 2.86 ± 0.04 µm (n = 397) and a very narrow dis-
tribution of diameters. This highly monodispersed distribution 
results from the relatively uniform size of the porous CaCO3 
template used to fabricate the MPs [10c,d] and represents an 
advantage over other production techniques that result in 
microparticle formulations with higher size distribution.[15] 
The MPs size monodispersity is extremely important in drug 
delivery applications, and in particular in pulmonary drug 
delivery, not only to ensure uniform drug load and release 
profiles but also well-defined aerodynamic properties.
High-resolution SEM images also confirmed that 
the roughness from the porous structure of the CaCO3 
(Figure 1C1,C2) template was well preserved in the gelatin 
microgels (Figure 1D1,D2) although the surface seems 
to be smother than that of CaCO3 templates. Besides the 
enabling the fine control over MPs dimension in the fabri-
cation process, the use of a CaCO3 as porous template also 
aimed at increasing the MPs porosity and hence improving 
their dispersibility and aerodynamic performance through 
the increase of surface roughness and the number of 
contact points (cohesiveness) between MPs.[15a] Moreover, drug 
carriers with high bulk porosity generally have higher bulk 
surface area which leads to enhanced drug loading efficiency 
and favored release compared to compact structures obtained 
by other particle production techniques such as emulsification, 
which limit the absorption and subsequent release of encapsu-
lated drugs.[10c]
A number of complementary techniques were used to 
confirm the suitability of the fabrication process employed 
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and the shape and size of the MPs. Complete CaCO3 
template removal from the MPs was confirmed by energy 
dispersive spectroscopy (EDS) analysis as the calcium 
element is not detected on the particles (see Figure 1E). Addi-
tionally, EDS analysis also revealed the presence of iron ele-
ment (Fe) corresponding to the Fe3O4 core of SPIONs in the 
MPs. Transmission electron microscopy (TEM) images of the 
MPs are shown in Figure 1F and confirmed the spherical shape 
and the MPs diameter (inset of Figure 1F) assessed by SEM. 
Furthermore, a cross-section analysis showed that SPIONs 
were both at the surface of the MPs, as assessed from EDS 
analysis, and incorporated within the MPs core (Figure 1F).
The developed MPs suspended in water also exhibited a 
spherical shape replicating the original form of the CaCO3 
templates with a diameter of 4.19 ± 0.05 µm (n = 223) 
(Figure 2A1,A2). As expected, the diameter of the hydrated 
MPs was found to be higher than that of the dried MPs, 
2.86 ± 0.04 µm, due to the adsorption of water which causes 
Adv. Healthcare Mater. 2018, 7, 1800124
Figure 1. Shape, size, size distribution, and surface morphology of dried MPs. A) SEM images. B) Histogram of the distribution frequency of the diam-
eters of dried MPs and normal distribution curve. C) High-resolution SEM images revealing the calcium carbonate porous surface topography. D) High-
resolution SEM images revealing the MPs surface topography. E) EDS spectrum of MPs: elemental analysis: C (54.6% ± 1.3%), O (29.2% ± 0.9%), 
N (10.9% ± 1.8%), Fe (3.5% ± 0.3%), S (1.8% ± 0.1%). F) TEM image of the cross-section of an MP (scale bar represents 0.2 µm) where black dots 
represent magnetic nanoparticles; inset: image of MPs (scale bar represents 2 µm).
Figure 2. Assessment of shape, size, and size distribution of hydrated MPs by confocal microscopy. A) MPs produced with BSA are autofluorescent in 
the red channel (560 nm): (A1) two dimension image, (A2) three dimension image. B) Histogram of the diameters frequency distribution of hydrated 
MPs and normal distribution curve. C) MPs produced with BSA-FITC showing fluorescence for the green channel (C1), red channel (C2), and overlay 
of green and red channels (C3).
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swelling of gelatin/BSA MPs. The frequency histogram of 
diameter distribution of the hydrated MPs is presented in 
Figure 2B along with the corresponding normal distribution 
function and as observed for the dried MPs, hydrated MPs also 
have a remarkably narrow size distribution.
To evaluate the carrier pH responsiveness, MPs were dis-
persed in phosphate buffered saline (PBS) 7.4 and 5.4 and their 
diameter analyzed by confocal microscopy. These pH values 
were chosen to mimic the pH under physiological conditions 
(7.4) and the pH in the macrophage phagosomes that are 
known to vary from 4.5 to 6.2.[16] The MPs were found to be pH 
sensitive exhibiting a decrease in diameter from 4.37 ± 0.04 µm 
(n = 342) at pH 7.4 to 3.64 ± 0.05 µm (n = 218) at pH 5.4. A 
similar behavior has been previously described for gelatin 
microgels crosslinked with genipin.[10c] According to this study, 
most of the primary amine groups of the gelatin/BSA matrix 
are consumed in the crosslinking reaction with genipin and 
therefore the remaining ionizable groups are carboxylic acids 
(aspartic acid and glutamic acid) that have a lower degree of 
protonation at pH 7.4 than at pH 5.4. The higher charge den-
sity of the MPs matrix at pH 7.4 leads to an increased repulsion 
between protein chains within the microgel and consequently 
to higher swelling ratios.
In order to confirm the incorporation of BSA within the 
MPs, BSA-fluorescein isothiocyanate (FITC) instead of BSA was 
used in the MPs production process. The green fluorescence 
observed by confocal microscopy within the MPs (Figure 2C1) 
confirms the presence a relatively uniform distribution of BSA 
in the particles volume, which are autofluorescent in the red 
channel.
The shape and size of the MPs are particularly important fea-
tures to meet the phagocytosis range of macrophages. Indepen-
dently of their dry or hydrated form, MPs physical diameter is 
within the range of macrophages action, normally in the range 
of 1–6 µm.[8b]
The SPIONs content in the MPs was quantitatively evalu-
ated by thermal gravimetric analysis (TGA). Figure 3A rep-
resents a TGA experiment of dried MPs. Free SPIONs were 
used as experimental controls. In the MPs there is an ini-
tial mass loss due to the removal of strongly adsorbed water 
from the MPs. A second accentuated mass loss starting at 
about 200 °C corresponds to the combustion of organic 
matter in the MPs. In free-SPIONs, only the initial water 
mass loss is detected. The mass percentage of SPIONs in 
the dry MPs was calculated to be 10.1% ± 2.2% w/w (a cor-
rection was made for the mass loss of free SPIONs) and 
their water content was determined to be 3.0% ± 0.8% w/w 
(n = 6, mean and two standard deviations from the mean 
of six experiments, for a level of confidence 95%). The pro-
duced MPs have similar SPIONs content to other MPs for-
mulations designed for pulmonary delivery. For example the 
ones reported by McBride et al.[15a] and Stocke et al.[15b] for 
targeted treatment of lung cancer.
The magnetic responsiveness of MPs was qualitatively 
confirmed by sorting the MPs from a water suspension using 
a permanent rare-earth magnet (inset of Figure 3B) and the 
magnetic behavior of dried MPs was assessed by SQUID 
(superconducting quantum interference device) analysis. 
The saturation magnetization of MPs at room temperature 
was determined to be 2.08 emu g−1, exhibiting zero coercive 
field and remanence magnetization at zero magnetic field 
(Figure 3B), which is consistent with a superparamagnetic 
behavior provided by the SPIONs incorporated within MPs. 
In superparamagnetic particles, a magnetic dipole moment 
is induced only when an external magnetic field is applied 
allowing the possibility of externally controlling the release 
of a loaded drug. As expected, the saturation magnetiza-
tion value of the MPs is lower than that of free-SPIONs 
(46.01 emu g−1), reflecting their low magnetic material con-
tent (10.1% ± 2.2% w/w).
2.2. Characterization of Developed P3 Loaded MPs Systems
2.2.1. P3 Loading Assay
A 48 h incubation period of MPs with a P3 drug solution was 
selected based on the preoptimization studies which indicated 
that this is the time required to attain the maximum loading 
(data not shown). The loading efficiency results are summa-
rized in Table 1.
The loading efficiency of P3 into MPs was 82.7% ± 0.9%. 
This value is comparable to other dry powders produced 
by spray-drying and it is significantly higher than other 
Adv. Healthcare Mater. 2018, 7, 1800124
Figure 3. Magnetic responsiveness of MPs: A) TGA analysis of MPs and free-SPIONs for the quantification of SPIONs available in MPs. 
B) Magnetization curve as function of the applied magnetic field (Ms = 2.08 emu g−1) confirming the superparamagnetic behavior of MPs. [Inset of (B)] 
Magnetic sorting of MPs from a water suspension using a permanent rare-earth magnet.
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microparticulate drug carrier systems, e.g., fabricated by emul-
sion/solvent evaporation technique.[17] The use of BSA as 
microgel filler was envisioned to improve the loading capacity 
of MPs for P3 by synergistically promoting a favorable drug/
matrix interaction while preventing the collapse of the MPs and 
further increase their total surface area. Moreover, the binding 
of hydrophobic molecules to BSA is reversible which allows the 
release of P3 from the MPs.[18]
2.2.2. P3 Loaded MPs Physicochemical Characterization
The specific surface area and the pore width of the P3 loaded 
MPs (P3-MPs), determined by the Brunauer–Emmett–Teller 
(BET) method, were 12.250 m2 g−1 (error of ≈2%) and 2.183 nm, 
respectively. Comparatively, the surface area of the P3-MPs is 
significantly higher than that of nonporous compact particles 
with an identical diameter (0.8 m2 g−1)[19] and even higher than 
that of the original CaCO3 templates (8.8 ± 0.3 m2 g−1).[20] Inter-
estingly, P3-MPs also present a considerably higher specific 
surface area than other anti-TB drug loaded microparticles used 
for pulmonary drug delivery. For example, Sethuraman and 
Hickey[21] reported that rifampicin-loaded PLGA microparticles 
had a specific surface area of 3.13 m2 g−1 while Tewes et al.[13f ] 
reported on inhalable trojan particles having a specific sur-
face area in the range of 1.4–6.8 m2 g−1. The higher specific 
surface area of the developed P3-MPs is certainly related with 
the porous morphology of the template used to fabricate them 
and is reflected on its high drug loading efficiency and may 
result in improved aerodynamic properties. Collectively, these 
set of properties suggest that the developed system might have 
enhanced characteristics to be applied as anti-TB drug carriers 
aimed at pulmonary delivery.
The aerodynamic properties of the P3-MPs are critical for 
their deposition in the lower lung airways. In order to reach 
the alveoli the particles must have an aerodynamic diameter 
(da) in the range of 1–5 µm.[7] The P3-MPs true density was 
determined by gas pycnometry and the value obtained was 
1.49 ± 0.02 g cm−3. The aerodynamic diameter (da) relates to the 













where ρp is the apparent particle density, ρ0 is the standard par-
ticle density (1 g cm−3), and χ is the particle shape factor that 
is 1 for spherical particles. It should be noted that the ρp can 
be lower than the material true density if the particle is porous 
as ρp is equal to the mass of a particle divided by its apparent 
volume that is the total volume of the particle excluding open 
pores but including closed pores.[22b,23] Using the geometric 
diameter provided by SEM analysis (2.86 ± 0.04 µm) and 
applying the formula above, we obtained an aerodynamic 
diameter of 3.5 ± 0.1 µm. However, the apparent density of 
the particles should be lower than the P3-MPs true density 
and consequently, the aerodynamic diameter of the P3-MPs 
should be smaller than the above estimated value, yet within 
the 1–5 µm range required to favor P3-MPs deposition in the 
lower airways. As a comparison with other inhalable dry pow-
ders incorporating SPIONs, dense microparticles prepared by 
spray-drying and composed of lactose, doxorubicin and about 
10% w/w of SPIONs with a diameter of 1.6 µm have an aero-
dynamic diameter of 3.3 ± 1.7 µm [15a] and other based on man-
nitol with 13% w/w SPIONs with a diameter of 0.7 µm have an 
aerodynamic diameter of 4.5 ± 0.1 µm.[15b]
2.2.3. P3 Release Behavior
The release profile of P3 from MPs was studied under different 
conditions simulating the physiological environments to which 
they can be exposed and to evaluate the functionality of their 
inherent magnetic responsive character. The release profile of 
P3 from the MPs into PBS at 37 °C is shown in Figure 4A. The 
P3 release occurs as a burst release in the first 6 h followed by 
a prolonged sustained release stage. During the first 6 h, the 
burst release of P3 is higher in PBS 5.4 reaching 40%, while 
in PBS 7.4 the release is more sustained reaching only 30%. 
Independently of the solution, the initial burst may be mainly 
related with the release of the easily accessible P3 from MPs 
surface which is dominated by the solubility of the drug in 
the solvent and by convection processes (in this case, shaking 
which was kept constant through experiments).
The sustained release that follows is attributed to P3 diffu-
sion through the polymeric matrix,[24] clearly demonstrating 
the favorable interfacial interaction between the drug and the 
carrier (BSA and gelatin). P3 shows a faster release at acidic 
pH which can be explained by the higher solubility of P3 in 
acidic medium due to the protonation of nitrogen atoms in 
their purine-based structure (positive charge), as well as the 
lower electrostatic interactions between the positively charged 
P3 and the protein matrix due to the higher protonation of 
their carboxylic groups at acidic pH. A similar pH triggered 
release behavior of positively charged drugs from micropar-
ticles and microcapsules was previously observed on other 
similar systems based on gelatin and BSA matrices.[10c,e,25] 
Moreover, MPs morphology remains relatively intact during 
the release assay (Figure S1, Supporting Information), and 
therefore the matrix degradation/erosion phenomena are 
not expected to significantly affect P3 release kinetics. Note 
however that these assays were performed in PBS without the 
presence of proteolytic enzymes which will certainly accel-
erate the degradation rate of the gelatin/BSA matrix, and 
Adv. Healthcare Mater. 2018, 7, 1800124
Table 1. Results from anti-TB drug loading in the developed MPs.
[P3]initial [µg mL−1] mP3 initial [µg] Number of MPs mP3 in MPsa) [µg] mP3 per MPa) [µg/MP] Loading efficiencya) [%]
21.4 37.5 (7.3 ± 0.8) × 106 31.0 ± 0.4 (4.2 ± 0.1) × 10−6 82.7 ± 0.9
a)Corresponds to the mean and two standard deviations of the mean of three independent experiments for a level of confidence of 95%.
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therefore, MPs erosion will have a relevant contribution for 
the P3 release kinetics in vivo. Since the pH of phagosomes 
varies from 4.5 to 6.2,[16] these results suggest that, it is likely 
that higher amounts of P3 drug are more prone to be released 
within these vesicles in infected macrophages, where Mtb 
resides and where P3 drug can be more effective.
In magnetic controlled drug delivery strategies, remote 
actuation on magnetic nanoparticles aims to generate heat by 
applying high frequency AMF producing a temperature-respon-
sive change in the release profile of the system or mechanical 
deformations of the carrier matrix induced by a low frequency 
AMF that can modulate the release behavior and where the heat 
effect is negligible or nonexistent.[14d] In this work we explored 
this last approach. The effect of an AMF on the P3 release was 
studied by exposing P3-MPs for 30 min to a magnetic field with 
different intensities (1.7 and 3 mT) and frequencies (1000, 500, 
and 100 Hz).
Considering the results obtained for P3 release in acidic 
pH and their relevance in the phagosome, the P3 release 
under AMF was assessed in PBS 5.4 and during the P3 sus-
tained release phase. The sustained release phase was deter-
mined to be from 24 h to 7 days in accordance to the results 
shown in Figure 4A. Although no variation in solvent tem-
perature was detected, the P3 release pattern was altered upon 
exposure to the AMF (Figure 4B), indicating a magnetically 
driven mechanical effect. An increase of 6.3% ± 1.3% in the 
P3 release was quantified after exposing the MPs to an AMF of 
3 mT and 1000 Hz, while in the absence of AMF, the cumula-
tive release was only 0.6% ± 0.9%. These results evidence that 
the applied AMF induces a tenfold increase in the P3 release. 
The percentage of P3 release due to the application of an 
AMF with different intensities and frequencies is represented 
in Figure 4C1,C2 where the Y-axis represents the increment 
observed in the cumulative release from the time point imme-
diately before magnetic actuation and after this treatment. As 
can be seen from the shown data, there is an increase in the 
P3 release percentage with the increase in frequency and also 
with the increase of the magnetic field intensity. These results 
suggest that upon actuation of an AMF and in the presence of 
SPIONs, the P3-MPs offer the capability to trigger and mod-
ulate P3 release profile, which could be adjusted to meet the 
needs and duration of an anti-TB therapy. Furthermore, our 
results are in agreement with other particulate systems using 
MNPs for controlled drug release upon exposure to AMF.[14a,26] 
For example, Guo et al.[26a] developed carboxymethyl dextran-
coated magnetoliposomes with 6% of SPIONs and found that 
the release of doxorubicin could be modulated by exposure to 
low frequency AMF (50 Hz, 15–45 mT). This study reported an 
increase in the release of doxorubicin with increasing intensity 
of the AMF without heat generation, suggesting that the trig-
gered release under AMF was primarily due to the drug leakage 
resulting from the physical deformation of the liposomes.
Adv. Healthcare Mater. 2018, 7, 1800124
Figure 4. A) Cumulative P3 release profile from the MPs in PBS at different pH [7.4 (blue), 5.4 (red)] and at 37 °C, for up to 7 days; values are 
represented by the mean with two standard deviations. B) Cumulative P3 release profile from the MPs in PBS 5.4 for 7 days under nonstimula-
tion (red) and upon the actuation of an AMF of 1000 Hz, 3 mT (green), for 30 min in the sustained release phase. Values are represented by 
mean with two standard deviations (level of confidence 95%). C) Increment of P3 release due to application of AMF with different frequencies 
(C1) and intensities (C2) in the sustained release phase and for 30 min. Horizontal lines and * symbol denote statistically significant differences 
(p < 0.0001).
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2.3. In Vitro Biological Assessment
A cytotoxicity screening was performed in both MPs and 
P3-MPs using L929 cells for 3 and 7 days in static and MF cul-
tures (Figure 5).
Overall, L929 in the presence of MPs and P3-MPs show 
viability values similar to cells cultured in MP-free conditions 
(L929+TCS). Moreover, there is an increase in L929 viability 
levels from day 3 to day 7 in static conditions, especially in 
conditions with increased number of MPs and in increased 
P3-MPs concentrations (2IC90 and 5IC90). As expected, cul-
turing L929 cells under the influence of an external magnetic 
stimulation (2 Hz, 0.2 mm horizontal displacement) showed 
no significant differences (p < 0.05) in the metabolic activity of 
these cells in both MPs and P3-MPs groups, suggesting no det-
rimental effects of MF to L929 cells.
The MTS assay performed in THP-1 macrophages for up to 
3 days in culture indicates that THP-1 metabolic activity is not 
affected by MPs, loaded or unloaded with P3 drug (p < 0.05) 
(Figure 6). Moreover, the concentration of MPs up to 5.9 × 105, 
which corresponds to 5IC90 in P3-MPs does not influence cell 
viability. This result confirms the noncytotoxic effect of MPs 
and P3-MPs to macrophage cells. The viability assay was also 
assessed in macrophages isolated from murine bone marrow. 
Overall, the absorbance values are lower than the ones detected 
for THP-1 cells and there is a decrease in cell viability from 
day 1 to day 3 in the presence of different concentrations of 
unloaded MPs (p < 0.05). Interestingly, when MPs are loaded 
with P3 drug, the values are maintained along the time in cul-
ture (Figure 6) and are increased in comparison to cell-MPs sys-
tems. These results suggest that although P3 drug was shown 
to have high anti-TB activity,[9b] it has no cytotoxic effect on 
murine bone marrow derived macrophages (mBMDM) when 
combined with the MPs. As for THP-1 cells, the MPs concentra-
tion and thus the amount of particles in contact with mBMDM, 
does not seem to influence cell viability levels. Moreover, after 
3 days in culture, the metabolic activity levels of mBMDM cul-
tured with P3-MPs are quite similar (p < 0.05) to mBMDM cul-
tured in P3-MPs and MPs free conditions.
In order to determine the intracellular fate, MPs at different 
concentrations (0.5–5 × 106) were cultured with mBMDM in 
static conditions (Figure 7A). After 6 h incubation MPs are 
internalized by macrophages without impacting cell behavior, 
even at the highest concentration used. Moreover, confocal 
microscopy analysis confirmed the cellular uptake and locali-
zation of the MPs within macrophage cytoplasm as cell 
Adv. Healthcare Mater. 2018, 7, 1800124
Figure 5. L929 metabolic activity cultured in the presence of P3-MPs and in MPs for 3 and 7 days in static and magnetic stimulation (MF) conditions 
assessed by MTS assay. Different inhibitory concentrations of P3 (0.5–5 IC90) were considered. Horizontal lines and * symbol denote statistically 
significant differences (p < 0.05). Moreover, L929+P3 represent P3 drug in MPs-free experimental control while L929+TCS (tissue culture coverslip) 
and L929+DMSO (dimethyl sulfoxide) represent the positive and negative control of cell viability, respectively.
Figure 6. Metabolic activity of THP-1 and murine bone marrow derived macrophages (mBMDM) cultured in the presence of MPs and P3-MPs for 1 and 
3 days. Different inhibitory concentrations of P3 (0.5–5 IC90) were considered. Horizontal lines denote statistically significant differences (p < 0.05). 
Cells represent macrophages cultured in the absence of P3-MPs or MPs. No significant differences were observed among conditions studied (p < 0.05).
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nuclei and MPs align in the same plan, confirming MPs inter-
nalization (Figure 7B). These results are in agreement with sev-
eral publications that state macrophages phagocytosis exhibits 
an internalization peak around 2 to 3 h upon contact with a 
foreign body.[27]
In summary, our results suggest the potential of the designed 
MPs for magnetically actuated anti-TB therapies. MPs could 
be easily up scaled with the desired drug by adapting the cast 
method to a microfluidic platform in order to automatize and 
enable mass production of MPs.[28] Likewise the applicability of 
MPs to the clinical area would include magnetotherapy devices 
that are relatively cheap and portable for generating the AMF 
and consequent activation of SPIONs to release the drug. Since 
the treatment requires medical monitoring, these devices could 
be available in healthcare facilities to which the patients would 
access periodically.
3. Conclusions
In this work we successfully designed a multifunctional micro-
particulate system with magnetic responsiveness for pulmo-
nary delivery of an anti-TB drug candidate (P3). The P3-MPs 
were developed using a cast method and their physical and aer-
odynamic properties favor alveoli deposition and phagocytosis 
by alveolar macrophages. Additionally, the P3-MPs present a 
pH sensitive drug release profile, showing increased but sus-
tained release rates in the acidic pH conditions of phagosomes, 
although P3 can also be released into the interstitial space in 
alveoli. Moreover, when an AMF was applied there was a ten-
fold increase in P3 release suggesting that an external AMF 
can remotely trigger and modulate drug release profile. These 
results may represent a major achievement for TB treatment as 
it would be possible to release a predetermined amount of drug 
at a predefined time and as often as needed according to the 
treatment requirements, thus improving treatment efficiency 
and patient compliance.
Overall, the developed MPs have shown potential to be used 
as inhalable drug carrier systems aiming at magnetically actu-
ated anti-TB therapies and with particular added value as car-
riers for delivering hydrophobic anti-TB drugs, highlighting 
their versatile and functional potential for clinically relevant 
applications in pulmonary drug delivery.
4. Experimental Section
Materials: For MPs production and characterization the following 
materials were used: sodium carbonate (Na2CO3, ≥ 99.5%), gelatin 
from porcine skin (powder, gel strength ≈300 g Bloom, Type A), BSA 
(99%), albumin-fluorescein isothiocyanate conjugate (BSA-FITC), 
ethylenediaminetetraacetic acid anhydrous (EDTA, 99.6%), dimethyl 
sulfoxide (DMSO, 99.99%), and PBS tablets and were purchased from 
Sigma-Aldrich; SPIONs in a aqueous dispersion (fluidMAG-UC/C:cationic 
charged, size 50 nm, w/v = 25 mg mL−1, polydispersity index 0.15) 
were purchased from Chemicell; genipin (99.7%) was purchased from 
Commercial Rafer, S.L. and calcium chloride (CaCl2, 100.2%) was 
purchased from VWR; glutaraldehyde was purchased from electron 
microscopy sciences and paraformaldehyde from Merck; HCl and NaOH 
(1 and 5 m) were used for pH adjustments and were purchased from 
Fischer Chemical; ultrapure water was used in all experiments. For cell 
culture studies the following materials were used: DMEM (D2902, low 
glucose – with 1000 mg L−1 glucose and l-glutamine, without sodium 
bicarbonate and phenol red), DMEM (D5523, low glucose – with 
1000 mg L−1 glucose and l-glutamine, without sodium bicarbonate, 
powder), sodium bicarbonate (100.0%) and phorbol 12-myristate 
13-acetate (PMA) were purchased from Sigma-Aldrich; fetal bovine 
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Figure 7. Assessment of MPs internalization by murine bone marrow derived macrophages (mBMDM). mBMDMs were cultured in different concentra-
tions of MPs for 6 h and stained with HE (A1-D1, 40× magnification) or visualized in a confocal microscope (A2-D2). The letters, A), B), C) represent 
0.5 × 106, 2.5 × 106, and 5 × 106 MPs mL−1, respectively. Letter D) represents an MPs-free control. (A2-D2): blue represent cell nuclei stained with DAPI 
and red corresponds to the autofluorescence of the developed MPs. The bottom images are cross-sections of the 3D reconstructions of the focal planes 
of mBMDM cultured with MPs (scale bar represents µm).
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serum (FBS), HEPES, sodium pyruvate, l-glutamine, and PBS were 
purchased from Gibco, antibiotic/antimicotic solution from Alfagene and 
4,6-diamidino-2-phenyindole dilactate (DAPI) from VWR.
Preparation of P3-MPs: The production process of P3-MPs is 
represented in Figure 8. CaCO3 MPs incorporating SPIONs (Fe3O4) and 
BSA were prepared by a coprecipitation reaction.[10] Commercial SPIONs 
(500 µg mL−1) were added to an aqueous solution of CaCl2 (0.33 m) 
and BSA (500 µg mL−1) was added to an aqueous solution of Na2CO3 
(0.33 m). The two mixtures were rapidly combined and the resultant 
mixture was heavily stirred (about 1000 rpm) for 30 s followed by a 
15 min resting period. The supernatant was removed by centrifugation 
and the particles were washed three times with ultrapure water. Then, 
particles were suspended in a gelatin solution (100 mg mL−1) at 45 °C for 
6 h under mild agitation. Afterward, cold water was rapidly added. The 
mixture was centrifuged and washed with ultrapure water at least five 
times before suspending the particles in an aqueous genipin solution 
(0.028 m) overnight and under stirring. Then, particles were centrifuged 
and washed three times with ultra-pure water before being suspended in 
an EDTA solution (0.2 m, pH 5.5) for 30 min. The microgel particles were 
suspended in water and heated at 75 °C for 20 min under mild agitation 
before being incubated in an aqueous solution containing the anti-TB 
drug P3 (25 µg mL−1) for 2 days under agitation. For that, a P3 stock 
solution (5 mg mL−1) was first prepared with DMSO. A working solution 
of 25 µg mL−1 was prepared by diluting an appropriate volume of the 
P3 stock solution in water (final solution with 0.5% DMSO). The P3-MPs 
were then washed to remove unloaded drug and freeze dried to obtain 
dry powders. In the freeze-drying process, P3-MPs were flash frozen in 
liquid nitrogen to ensure that the MPs are frozen in suspension thus 
reducing the probability of aggregation and then dried under reduced 
pressure.
Characterization of Unloaded MPs: The dry powders obtained by freeze 
drying unloaded MPs were analyzed by SEM, field emission scanning 
electron microscope with focused ion beam (FIB-SEM), and by TEM.
For the SEM analysis, samples were placed on aluminum stubs 
with double-sided carbon tape and covered with gold under an argon 
atmosphere using a sputter coater (Cressington, 108A). The SEM 
(JSM-6010 LV, JEOL, Japan) was operated using an acceleration voltage 
of 15 kV. Elemental analysis was performed with an EDS (INCAx-Act, 
PentaFET Precision, Oxford Instruments).
The surface morphology of developed MPs was observed using a 
high-resolution FIB-SEM (Auriga Compact, Zeiss) at an acceleration 
voltage of 5.00 kV. For this analysis, the MPs were deposited onto glass 
supports (≈1 cm diameter), mounted on aluminum stubs and coated 
with 1 nm of platinum under an argon atmosphere using a sputter 
coater (Leica EM ACE600).
TEM analysis was performed using a Jeol JEM 1400 equipment 
(EM 10C, Zeiss). Before analysis, dried MPs were fixed in a mixture of 
glutaraldehyde (2.5% v/v) and paraformaldehyde (2% m/v) in 0.1 m 
cacodylate buffer. MPs were afterward washed with the same buffer and 
post-fixed with osmium tetroxide (1% v/v) in cacodylate buffer before 
being washed and dehydrated with increasing concentrations of ethanol. 
The MPs were then embedded with epoxy resin and thin sections were 
obtained by ultramicrotomy.
The shape and size of the MPs in ultrapure water (hydrated MPs) 
were analyzed by confocal laser scanning microscopy (Leica, model 
TCS SP8) using a laser excitation wavelength of 560 nm and taking 
advantage of MPs autofluorescence. The effect of pH on the diameter 
of the MPs has also been investigated by confocal microscopy with MPs 
dispersed in PBS at pH 7.4 (PBS 7.4) and at pH 5.4 (PBS 5.4).
Dried and hydrated MPs diameter measurements from SEM and 
confocal analysis were performed using software ImageJ (ImageJ 1.48v 
Wayne Rasband, NIH, USA, http://imagej.nih.gov/ij). The histogram of 
the frequency of diameter distribution and the corresponding normal 
distribution function has been derived from these assays for the dried 
and hydrated MPs.
To confirm the incorporation of BSA into the MPs, BSA-FITC, instead 
of BSA, was used to prepare MPs according to the procedure described 
in Preparation of P3-MPs. The BSA-FITC MPs were protected from light 
during the experimental setup and analyzed by confocal laser scanning 
microscopy with an excitation laser at 488 nm for the detection of FITC, 
a fluorescent chemical compound.
The size distribution of the MPs in aqueous solution was also 
qualitatively assessed by flow cytometry using the forward scatter 
detector for analyzing particle size and a side scatter detector for 
determining complexity of the MPs in an FACS ARIA cytometer 
(BD Biosciences).
The mass percentage of SPIONs incorporated into the unloaded MPs 
was determined by TGA with a simultaneous thermal analyzer (model 
STA7200, Hitachi). Dry MPs (2–4 mg) were placed in a platinum crucible, 
using an empty crucible as reference. The temperature of the furnace 
was raised to 105 °C at a rate of 10 °C min−1 and then isothermally 
held at this temperature for 10 min, under a nitrogen atmosphere, to 
remove the strongly adsorbed water content. The temperature was then 
increased to 600 °C at 20 °C min−1 under an oxygen atmosphere and 
isothermally held for 20 min in order to completely burn the organic 
component of MPs. The mass change events were recorded as function 
of the temperature. The mass percentage of SPIONs in the MPs was 
calculated from the difference between the initial mass of MPs and the 
total mass loss. Additionally, the water percentage of MPs corresponds 
to the mass loss of MPs until 105 °C.
The magnetic properties of the MPs were assessed using an 
SQUID-VSM magnetometer (Quantum Design) in dry MPs with a mass 
of sample of 3.2 mg at room temperature and under a magnetic field up 
to 20 kOe. For comparison purposes a study was also performed for the 
purchased SPIONs in the same conditions and using a mass of sample 
of 2.2 mg.
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Figure 8. Production process of MPs and loading of anti-TB drug P3 within the produced MPs.
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Characterization of Developed P3-MPs: Assessment of P3 Loading 
Efficiency: About 7.3 × 106 MPs were suspended in a P3 working solution 
prepared as described in Preparation of P3-MPs. The concentration 
of MPs (2.9 ± 0.8) × 107 MPs mL−1 was previously determined using 
disposable cell counting chambers (Hycor Biomedical Ltd) under a 
microscope (Leica DM750). The MPs were incubated in the P3 solution 
for 2 days at room temperature under mild agitation and protected from 
light. Afterward, MPs were collected by magnetic separation and the 
concentration of unloaded P3 in the supernatant was determined using 
a microplate reader (SYNERGY HT, Bio-tek instrum). The absorbance 
was measured at 420 nm and five readings were made for each assay. 
Three independent loading assays were performed. P3 concentration 
was determined using a calibration curve (0, 1, 2.5, 5, 10, 15, 25 µg mL−1 
of P3) and the loading efficiency was calculated as
Loading efficiency % ((initial amount of P3 amount of P3 insupernatant)/
initial amount of P3) 100
( ) = −
×  
Physicochemical Characterization of P3-MPs: The BET specific surface 
area and the pore size distribution of the P3-MPs were determined 
with a Quantachrome Autosorb IQ2 instrument. The sample (mass of 
68.5 mg) was outgassed at 50 °C for 12 h before the measurements. The 
pore size distribution was calculated from the sorption isotherm using 
quenched solid state functional theory for slit-shaped pores.
The true density of P3-MPs was determined by gas pycnometry using 
an Ultrapyc 1200e gas pycnometer from Quantachrome Instruments. 
Analysis was performed at 25.2 °C, with high purity nitrogen and 
99.0 mg of sample was used.
Assessment of Release Profiles: P3-MPs were suspended in 1 mL 
of either i) PBS 7.4 or ii) PBS 5.4, at 37 °C and under mild shaking 
conditions. At defined time periods (2, 4, 6, 24, 48, 72, 96, 168 h), 800 µL 
of the supernatant was collected, by magnetic separation of the particles, 
for assessing P3 concentration and an equal volume of fresh PBS with 
the specified pH was added. The absorbance of supernatant solution 
with released P3 was measured at 420 nm and PBS (7.4 or 5.4) was used 
as blank solution for background subtraction. Three independent release 
assays were performed for conditions i) and ii). The cumulative release 
of P3 was calculated using calibration curves obtained from standard 
solutions of P3 in PBS 7.4 and PBS 5.4 (minimum of six points were 
selected from 0 to 25 µg mL−1).
Since MPs were envisioned as magnetic responsive carrier systems, 
the release profile of P3 was assessed under the actuation of an AMF. 
The AMF was generated in a custom-designed solenoid device (800 turns 
per meter, length: 31 cm and internal diameter: 4.8 cm) by applying an 
alternating electric current with different intensities and frequencies.
First, the release assays of P3 from the MPs in PBS 5.4 medium was 
performed in the absence of an AMF (non-AMF) and P3 concentration was 
determined at defined time points: 2, 4, 6, and 24 h, using the procedure 
described above. The influence of AMF on P3 release was investigated 
selecting time points for magnetic actuation within the sustained release 
phase, previously assessed from the assays performed on the absence of 
AMF and determined to be from 24 h up to 7 days. In a typical experiment, 
the release assay proceeded under nonstimulated conditions up to 27 h 
and P3 release was assessed immediately before the application of the 
AMF. Then, the MPs were placed in the center of the solenoid and exposed 
to an AMF for 30 min. Immediately after AMF stimulation, samples were 
taken from the solenoid and P3 release determined. Afterward the assay 
continued in the absence of AMF and P3 release was assessed at 48, 72, 
96, and 168 h. In order to study the influence of magnetic stimulation, 
different magnetic field intensities and frequencies were investigated. 
Magnetic fields of 1.7 mT at 1000 Hz and 3 mT at 100, 500, and 1000 Hz 
were investigated. Release profile assays were performed in triplicate for 
each frequency and magnetic field intensity analyzed.
Cytotoxicity Assessment of Developed P3-MPs: A cell line of mouse 
fibroblasts (L929) acquired from the European Collection of Cell Cultures 
was cultured in contact with different concentrations of P3-MPs for 
1, 3, and 7 days. The cells were cultured in 96-well plates (Falcon) and 
grown as monolayers with a density of 1 × 105 cells cm−2 for 24 h in basal 
culture medium composed of DMEM with phenol red supplemented 
with 10% FBS and 1% antibiotic/antimicotic solution. Then, culture 
medium was removed and replaced with culture medium with 6.2 × 103, 
1.2 × 104, 2.5 × 104, and 6.2 × 104 P3-MPs, corresponding to estimated P3 
concentrations ranging from 0.15 to 1.5 µg mL−1. The selected range of 
P3 concentration corresponds to multiples of the inhibitory concentration 
IC90 (½IC90, 1IC90, 2IC90, and 5IC90), which measures the effectiveness 
of P3 in inhibiting 90% of Mtb bacilli, as previously established.[9b]
Cell metabolic activity was assessed with MTS assay (Cell Titer 96 
Aqueous Solution Cell Proliferation Assay, Promega). Briefly, cells were rinsed 
in PBS and the MTS solution was mixed with FBS-free and phenol red-free 
culture medium in a 1:5 ratio. Then, cells were incubated for 3 h at 37 °C 
in a 5% CO2 atmosphere. After this period, the supernatant was collected 
and the absorbance read at 490 nm (Synergy HT, Bio-TeK Instruments). 
The cell response to P3-MPs was assessed under a continuous magnetic 
field stimulation provided by a magnefect nanodevice (nanoTherics Ltd, 
UK) composed by an oscillating magnet array system (2 Hz, 0.35 T). Cells 
cultured under static conditions and in the presence of unloaded MPs or 
in contact with P3 drug without MPs were assessed as negative controls. 
Three independent assays with five replicates were considered.
Isolation and Differentiation of Macrophages: Isolation and 
Differentiation of Murine Bone Marrow Derived Macrophages (mBMDM): 
mBMDMs were isolated from 8 to 12-week-old C57BL/6 mice obtained 
from Charles River (Barcelona, Spain) housed under specific-pathogen-
free conditions with food and water ad libitum at the Life and Health 
Sciences Research Institute (ICVS).
After mice euthanasia, the femurs and tibias were removed under 
aseptic conditions and flushed with DMEM supplemented with 
10 × 10−3 m HEPES, 1 × 10−3 m sodium piruvate, 10 × 10−3 m l-glutamine 
and 10% heat-inactivated fetal bovine serum (complete DMEM). 
The resulting cell suspension was centrifuged and resuspended in 
complete DMEM with 20% of L929 cell conditioned medium (LCCM), 
at a final concentration of 5 × 105 cell mL−1. A volume of 8 mL was 
distributed per petri dish (Sterilin Limited), and cells were further 
incubated at 37 °C in a 5% CO2 atmosphere. Four days after plating, 
10 mL of complete DMEM supplemented with 20% of LCCM (a colony-
stimulating factor that promotes murine monocytes differentiation 
into macrophages) was added to the cells and at day 7 the cells 
were confirmed to be differentiated in macrophages. At this time, 
supernatants were discarded and cells were harvested gently with a cell 
scrapper in ice cold PBS. Thereafter, cells were centrifuged, distributed 
in tissue cultured 24-well plates at a density of 5 × 105 cell per well and 
incubated at 37 °C in a 5% CO2 atmosphere.
Culture and Differentiation of THP-1 Macrophages: Human macrophages 
derived from the cell line THP-1 were differentiated into macrophage-like 
cells by incubating the cells with phorbol 12-myristate 13-acetate (PMA, 
50 ng mL−1) for 3 days. Afterward, cells were confirmed to be completely 
differentiated and were ressuspended in fresh media (DMEM) to a 
concentration of 2 × 105 cells per mL. Then, THP-1 cells were plated on a 
tissue culture 24 well plate and incubated at 37 °C in a 5% CO2.
Viability of Macrophages (mBMDM and THP-1) in the Presence of 
MPs and P3-MPs: Both mBMDM and human THP-1 macrophages 
were incubated with different concentrations of P3-MPs corresponding 
to ½IC90, 1IC90, 2IC90, and 5IC90 dosage of P3 drug. These P3 drug 
concentrations correlate in number to 5.9 × 104, 1.2 × 105, 2.3 × 105, 
3.6 × 105, and 5.9 × 105 of unloaded MPs. Unloaded MPs were used 
as experimental controls. MPs and P3-MPs were tested in duplicates 
for each of the above multiples of IC90 concentrations and time point. 
The incubation times with MPs and P3-MPs were 24 and 72 h prior cell 
metabolic activity evaluation with MTS assay (Cell Titer 96 Aqueous 
Solution Cell Proliferation Assay, Promega) performed as described in 
Cytotoxicity Assessment of Developed P3-MPs.
Assessment of MPs Internalization by mBMDM: After the differentiation 
of mBMDM, as described in Isolation and Differentiation of Macrophages: 
Isolation and Differentiation of Murine Bone Marrow Derived Macrophages, 
mBMDM at a density of 5 × 105 cells per well were incubated in 24 well 
coverslips for 6 h with different amounts of MPs, corresponding to 
0.5 × 106, 2.5 × 106, and 5 × 106.
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After each time point, cells were rinsed with PBS, fixed and analyzed 
for HE staining using standard protocols or stained with 4,6-diamidino-
2-phenyindole dilactate (DAPI) for 10 min. Samples were then observed 
and analyzed in an optical microscope (OLYMPUS BX61 microscope) 
and in a confocal laser scanning microscope (TCS SP8, Leica with a 
LASX software vs. 8), respectively.
Statistical Analysis: Data are represented by mean ± two standard 
deviations for a level of confidence of 95% with the exception of in vitro cell 
culture assays whose data is represented by mean ± one standard deviation.
Statistical analysis was carried out using a 2-Way ANOVA followed 
by the Tukey multiple comparison test to assess significant differences 
among studied conditions, using GraphPad Prism software (version 6). 
An exception was made for the release profile of P3 under an AMF. In 
this case statistical analysis was performed by one way ANOVA followed 
by Kruskal–Wallis multiple comparison test.
A minimum of 95% confidence interval was considered for all 
measurements (p < 0.05). The minimum number of samples and the 
number of independent assays are indicated in each quantitative assay 
performed. Statistical significant values and associated degree of 
confidence (p < 0.05) are denoted by the horizontal lines and symbols 
represented in the graphs.
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